Nxera Pharma Investor Relations Material
Latest events
Q1 2025
Nxera Pharma
Corporate Presentation
2 Jul, 2025
Investor Presentation
19 Jun, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nxera Pharma Co. Ltd
Access all reports
Sosei Group Corporation, also known as Sosei Heptares, is a biopharmaceutical company that specializes in the development of drugs using its proprietary G protein-coupled receptor (GPCR) targeted StaR technology and structure-based drug discovery (SBDD) platform. The company's product lineup includes medicines such as Ultibro, Seebri, Enerzair, Breezhaler, Pivlaz, and Oravi. Sosei Group Corporation is headquartered in Chiyoda-ku, Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Key slides for Nxera Pharma Co. Ltd
Investor Presentation
Nxera Pharma Co. Ltd
Investor Presentation
Nxera Pharma Co. Ltd
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
4565
Country
🇯🇵 Japan